Protein Biomarker Discovery In Neurotrauma

Protein Biomarker Discovery In Neurotrauma

A major focus of the Hinson lab is the acquisition and analysis of high dimensional proteomic data, especially using mass spectrometry techniques (including label-free MS) and highly sensitive, digital multiplexed immunoassays (SIMOA). Our preliminary work showed MS techniques are feasible and may be informative in blood samples acquired in acute TBI. Using SIMOA, we measured neuronal and glial cell injury markers contained in extracellular vesicles.

We have also identified candidate biomarkers that associate with progression of intracranial hemorrhage using global discovery mass spectrometry.

We are also interested in pathway analysis, e.g., using the identified candidate markers to characterize biologically plausible pathways that might contribute to secondary brain injury in neurotrauma.

 

Relevant Publications

  1. Hinson HE, Jacobs J, McWeeney S, Wachana A, Shi T, Martin K, Rodland K. Antibody-Free Mass Spectrometry Identification of Vascular Integrity Markers in Major Trauma. Neurotrauma Rep. 2021;2(1):322-329
  2. Creech M, Carvalho L, McCoy H, Jacobs J, Hinson HE. Mass Spectrometry-Based Approaches for Clinical Biomarker Discovery in Traumatic Brain Injury. Curr Treat Options Neurol. 2022 Dec;24(12):605-618.
  3. Guedes VA, Mithani S, Williams C, Sass D, Smith EG, Vorn R, Wagner C, Lai C, Gill J, Hinson HE. Extracellular Vesicle Levels of Nervous System Injury Biomarkers in Critically Ill Trauma Patients with and without Traumatic Brain Injury. Neurotrauma Rep. 2022;3(1):545-553. 
  4. Shah VA, Hinson HE, Reznik ME, Hahn CD, Alexander S, Elmer J, Chou SH. Common Data Elements for Disorders of Consciousness: Recommendations from the Working Group on Biospecimens and Biomarkers. Neurocrit Care. 2023 Dec 12;. doi: 10.1007/s12028-023-01883-2.  PubMed PMID: 38087173.